Latest Videos

Managing Brachytherapy & Radiation Oncology Patients During the COVID-19 Crisis

Managing Brachytherapy & Radiation Oncology Patients During the COVID-19 Crisis

Posted by | Apr 2020

Brian J. Moran, MD, Medical Director of the Chicago Prostate Cancer Center, discusses the impact of the COVID-19 pandemic on treatment for both low- and high-risk prostate cancer patients within their clinic. He explains how the pandemic has caused an increased patient interest in brachytherapy over external beam radiation due to shorter treatment times, that the American Brachytherapy Society advises that low-risk patients receive a delay in treatment so patients with high-risk, unfavorable cancers can be treated first, and how the clinic is implementing telemedicine and social-distancing practices in waiting rooms to reduce COVID-19 exposure.

Read More
Point-Counterpoint: Oncotype Dx Genomic Prostate Score in Active Surveillance – Canary PASS Study

Point-Counterpoint: Oncotype Dx Genomic Prostate Score in Active Surveillance – Canary PASS Study

Posted by | Apr 2020

Daniel W. Lin, MD, and Eric A. Klein, MD, present a point-counterpoint on the conclusions of Dr. Lin’s recently published results of Canary PASS (Prostate Active Surveillance Study), which looked at the ability of the Oncotype DX genomic prostate score (GPS) for predicting adverse pathology (AP) in primarily low-risk prostate cancer patients undergoing active surveillance. Following each presentation, Dr. Lin and Dr. Klein also discuss several follow-up questions related to the study and, more broadly, the future of prostate cancer treatment with E. David Crawford, MD, Editor-in-Chief of Grand Rounds in Urology.

Read More
BCG Failure: Defining Failure and Managing Difficult Cases of Non-Muscle Invasive Bladder Cancer

BCG Failure: Defining Failure and Managing Difficult Cases of Non-Muscle Invasive Bladder Cancer

Posted by | Apr 2020

Donald L. Lamm, MD, FACS, Director of BCG Oncology and Clinical Professor of Surgery at the University of Arizona College of Medicine, discusses the criteria required of studies looking for alternative drug therapies to Bacillus Calmette-Guerin (BCG) to treat non-muscle invasive bladder cancer (NMIBC). Because there are many BCG refractory, recurrent, intolerant, and unresponsive patients, and because there is a global shortage of BCG, new drugs are much needed. To get funding, studies will require FDA approval, and Dr. Lamm suggests that researchers are more likely to receive approval quickly by using standard definitions and providing clear follow-up and end-points in their proposals.

Read More